ArticleTargeted oncology2024
Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study.
Gwan Hee Han et al.PubMed ↗Publisher ↗
No numbers read from the abstract.